Glymedus PM 2mg/500mg/15mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which improves insulin responsiveness in adipose tissue, muscle, and the liver. The combined action of these agents addresses multiple pathophysiological defects associated with type 2 diabetes, providing better glycemic control than monotherapy. Glymedus PM is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. It should be used with caution in patients with hepatic or renal impairment and contraindicated in those with severe heart failure or hypersensitivity to any component. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and weight gain. Regular monitoring of blood glucose, renal and liver function tests is recommended during therapy to optimize treatment outcomes and minimize risks.